The wobbler mouse, an ALS animal model
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
This review article is focused on the research progress made utilizing the wobbler mouse as animal model for human motor neuron diseases, especially the amyotrophic lateral sclerosis (ALS). The wobbler mouse develops progressive degeneration of upper and lower motor neurons and shows striking similarities to ALS. The cellular effects of the wobbler mutation, cellular transport defects, neurofilament aggregation, neuronal hyperexcitability and neuroinflammation closely resemble human ALS. Now, 57 years after the first report on the wobbler mouse we summarize the progress made in understanding the disease mechanism and testing various therapeutic approaches and discuss the relevance of these advances for human ALS. The identification of the causative mutation linking the wobbler mutation to a vesicle transport factor and the research focussed on the cellular basis and the therapeutic treatment of the wobbler motor neuron degeneration has shed new light on the molecular pathology of the disease and might contribute to the understanding the complexity of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Atkin, J. D., Farg, M. A., Walker, A. K., McLean, C., Tomas, D., & Horne, M. K. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.02.009 · Cited by 350 · cited 1×
“Likewise, elevated levels of UPR markers are seen in CSF and spinal cords of sALS patients (Atkin et al. 2008).”
RetractedDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 2×
“2 Dominant Profilin 1 (PFN1) Actin filament assembly (Wu et al. 2012) 105550 614260 FTD-ALS 9p21 Dominant C9ORF72 Unknown function (DeJesus-Hernandez et al. 2011; Renton et al. 2011) early event in at least some sALS cases, and TDP-43 mislocalisation and inclusion bodies are seen not only in motor…”
BackgroundA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409 · cited 2×
“…1 (PFN1) Actin filament assembly (Wu et al. 2012) 105550 614260 FTD-ALS 9p21 Dominant C9ORF72 Unknown function (DeJesus-Hernandez et al. 2011; Renton et al. 2011) early event in at least some sALS cases, and TDP-43 mislocalisation and inclusion bodies are seen not only in motor neurons but…”
BackgroundTDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 3×
“TDP-43 has been shown to be a major constituent of these inclusions and is a common feature for both fALS and sALS (Neumann et al. 2006; Sreedharan et al. 2008).”
Backgroundβ-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 2×
“cologically induced up-regulation of EAAT2 transcription could show beneficial effects in ALS model mice (Rothstein et al. 2005); suggesting that decreased EAAT2”
BackgroundSelective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265 · cited 4×
“…in optineurin (ALS12 locus), a protein involved in the maintenance of the Golgi complex, exocytosis and various aspects of Golgi trafficking, lead to increased NF-jB activation, which is also upregulated in sALS and thus, might be connected with motor neuronal cell death (Maruyama et al. 2010).”
BackgroundInfluentialExome Sequencing Reveals VCP Mutations as a Cause of Familial ALS
Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V. M., Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wuu, J., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.036 · Cited by 1,235 · cited 2×
“3 Dominant Valosin-containing Protein (VCP) ER protein export, autophagy (Johnson et al. 2010) 300857 ALS15 Xp11.”
BackgroundAstrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007) · Nature Neuroscience · doi:10.1038/nn1876 · Cited by 1,220
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011) · Nature · doi:10.1038/nature10353 · Cited by 1,174
Orchestrating the unfolded protein response in health and disease
Kaufman, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216886 · Cited by 1,015 · cited 2×
“The first step is recognition of mis-folded proteins by ER-resident chaperones, then the cells activate a collection of signal transduction pathways defined as the ‘‘unfolded protein response’’ (UPR), whose goal is to re-establish the cellular homeostasis (Kaufman 2002).”
BackgroundRosen, D. (1993) · Nature · doi:10.1038/364362c0 · Cited by 922
ALS‐associated fused in sarcoma (FUS) mutations disrupt Transportin‐mediated nuclear import
Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M. E., Mackenzie, I. R. A., Capell, A., Schmid, B., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.143 · Cited by 836
Yang, Y., Hentati, A., Deng, H.-X., Dabbagh, O., Sasaki, T., Hirano, M., Hung, W.-Y., Ouahchi, K., Yan, J., Azim, A. C., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-160 · Cited by 743
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration
Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M., & Baloh, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908767106 · Cited by 706
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646 · cited 2×
“neuroinflammation is beneficial and/or harmful for motor neuron survival in ALS (Philips and Robberecht 2011) and the wobbler mouse.”
BackgroundMolecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615 · cited 18×
“These mutations are dominantly inherited indicating that a gain of toxic function rather than loss-of-SOD1 function underlies the disease mechanism (Ferraiuolo et al. 2011).”
BackgroundInfluentialDeleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS
Chow, C. Y., Landers, J. E., Bergren, S. K., Sapp, P. C., Grant, A. E., Jones, J. M., Everett, L., Lenk, G. M., McKenna-Yasek, D. M., Weisman, L. S., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.010 · Cited by 407
ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)
Parkinson, N., Ince, P. G., Smith, M. O., Highley, R., Skibinski, G., Andersen, P. M., Morrison, K. E., Pall, H. S., Hardiman, O., Collinge, J., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000231510.89311.8b · Cited by 395 · cited 6×
“…multivesicular body protein 2B (CHMP2B), a component of the endosomal sorting complex, causes vacuolisation, lysosomal mislocalisation and impaired autophagy in cultured cells and has been associated with frontotemporal dementia (FTD; FTD3) and ALS (ALS17) (Parkinson et al. 2006; Cox et al. 2010).”
BackgroundInfluentialLoss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis
Kraemer, B. C., Schuck, T., Wheeler, J. M., Robinson, L. C., Trojanowski, J. Q., Lee, V. M. Y., & Schellenberg, G. D. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0659-0 · Cited by 350 · cited 4×
“Mouse (Gurney et al. 1994), and others reviewed in (Bruijn et al. 2004) Transgenic SOD1 mutant variants Zebrafish (Lemmens et al. 2007; Ramesh et al. 2010) Alsin (ALS2) Alsin KO mouse Mouse (Devon et al. 2006) Alsin knock down Zebrafish (Gros-Louis et al. 2008) FUS (ALS6) Transgenic human WT FUS Mouse (Mitchell et al.…”
BackgroundInfluentialErythropoietin as an antiapoptotic, tissue-protective cytokine
Ghezzi, P., & Brines, M. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401450 · Cited by 327 · cited 1×
“In recent years, it has widely been demonstrated that the neuroprotective effect of erythropoietin and its derivates is related to both, trophic-antiapoptotic activity and antiinflammatory action (Ghezzi and Brines 2004).”
BackgroundMutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)
Cox, L. E., Ferraiuolo, L., Goodall, E. F., Heath, P. R., Higginbottom, A., Mortiboys, H., Hollinger, H. C., Hartley, J. A., Brockington, A., Burness, C. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009872 · Cited by 262 · cited 4×
“Impairments of the cellular vesicle transport processes are also expected for fALS (ALS2, ALS8, ALS11, and ALS17) and thus might be a more general hallmark of ALS.”
BackgroundInfluentialDe Paola, M., Mariani, A., Bigini, P., Peviani, M., Ferrara, G., Molteni, M., Gemma, S., Veglianese, P., Castellaneta, V., Boldrin, V., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00020 · Cited by 75 · cited 5×
“…2008) VB3323, a TLR4 (Toll-like receptor 4) antagonist Beneficial, delayed motor impairment, decreased microglia activation (Fumagalli et al. 2006; De Paola et al. 2012) EPO (erythropoietin) Beneficial, improved motor performance, decreased astro- and microgliosis (Mennini et al.…”
BackgroundInfluentialSelf-citationALS and frontotemporal dysfunction: a review
Achi, E. Y., & Rudnicki, S. A. (2012) · Neurology Research International · doi:10.1155/2012/806306 · Cited by 74
Cited by
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Mejzini, R., Flynn, L. L., Pitout, I. L., Fletcher, S., Wilton, S. D., & Akkari, P. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01310 · Cited by 755
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Inflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550
The GARP Complex Is Involved in Intracellular Cholesterol Transport via Targeting NPC2 to Lysosomes
Wei, J., Zhang, Y.-Y., Luo, J., Wang, J.-Q., Zhou, Y.-X., Miao, H.-H., Shi, X.-J., Qu, Y.-X., Xu, J., Li, B.-L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.012 · Cited by 56
Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Metadata
- Authors
- Moser, J. M., Bigini, P., & Schmitt-John, T.
- Venue
- Molecular Genetics and Genomics
- Published
- 2013-03-29
- Volume
- 288
- Issue
- 5-6
- Pages
- 207-229
- ISSN
- 1617-4615 (ISSN-L)
- 1617-4623
- OpenAlex
- W2115597618
- Cited by
- 98
- References
- 24
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.